Summary & Overview
HCPCS Q0161: Chlorpromazine 5 mg Oral Anti-Emetic, Substitute for IV
HCPCS Level II code Q0161 denotes oral chlorpromazine hydrochloride 5 mg, an FDA-approved anti-emetic used as a complete therapeutic substitute for an IV anti-emetic during chemotherapy, with treatment limited to a 48-hour regimen. This designation matters nationally because it defines when an oral formulation may be billed and recognized as equivalent to IV anti-emetic therapy during infusion encounters, affecting clinical workflow and pharmacy use in oncology settings. Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn the clinical context for using oral chlorpromazine as an IV substitute during chemotherapy, typical sites of service where the code applies, and which payers are referenced. The publication summarizes how the code is characterized, highlights payer coverage presence, and outlines the operational implications for billing and service delivery at infusion centers and oncology clinics. Data not available in the input where specific coverage policies, reimbursement benchmarks, related taxonomies, and ICD-10 pairings would ordinarily be listed.
Billing Code Overview
HCPCS Level II code Q0161 represents chlorpromazine hydrochloride, 5 mg, oral, an FDA-approved prescription anti-emetic intended for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen. The service type is oral anti-emetic medication administration as a substitute for intravenous anti-emetic therapy during chemotherapy. The typical site of service is oncology infusion or chemotherapy treatment setting, including hospital outpatient infusion centers and freestanding oncology clinics.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology outpatient receiving moderately or highly emetogenic chemotherapy who requires an oral anti-emetic alternative to an IV agent at the time of treatment. The patient presents to the infusion clinic for scheduled chemotherapy. During pre-treatment assessment the nurse documents prior severe nausea with prior cycles or IV anti-emetic intolerance (e.g., IV access difficulty, prior IV reaction) and the oncologist orders an oral anti-emetic to be administered as a single-dose therapeutic substitute for an IV anti-emetic at the time of chemotherapy. Pharmacy dispenses Q0161 (chlorpromazine hydrochloride, 5 mg, oral) and the medication is given in the clinic immediately prior to or during chemotherapy. The regimen is limited to a maximum 48-hour dosage course per the code descriptor. Documentation includes indication (chemotherapy-induced nausea/vomiting prophylaxis or treatment), dose administered, timing relative to chemotherapy start, patient tolerance, and any subsequent anti-emetic orders for home use. Typical workflow participants include the oncologist, infusion nurse, clinic pharmacist, and medical billing staff who append appropriate modifiers and link to the supporting ICD-10 diagnosis for chemotherapy-induced nausea and vomiting or related codes when submitting claims to payors such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
23 |